Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The National Health Service named Oxford Vaccine Group’s Meningitis B vaccination programme one of the 70 most transformative discoveries over the past 70 years.

July 2018 marks the 70th birthday of the National Health Service. As part of the celebrations, the NHS’s I Am Research campaign highlights the research achievements that have improved health and care over the past 70 years, and shows how the work of National Institute for Health Research is helping to shape the future. Drawing on suggestions of experts from across the NIHR, the campaign presents 70 discoveries that have been the most transformative for both the NHS and its patients.

The Department of Paediatrics is very pleased that the Meningitis B vaccination programme featured among the 70 discoveries – particularly since the Oxford Vaccine Group administered the very first paediatric dose of the vaccine!

Meningococcal disease is caused by the bacterium Neisseria meningitidis, and can lead to meningitis (inflammation of the membranes that surround the brain) and septicaemia (blood poisoning). Meningitis B accounts for about 90% of meningococcal infections in the UK, each year there are between 500 and 1700 cases. It can affect all age groups, but the rates of disease are highest in children under five years of age, and most cases are seen in babies under the age of one. It is also often seen in teenagers aged between 15 and 19.

Introduction of the Meningitis B vaccination programme has seen cases in infants aged one or less drop by 42%. Currently Oxford Vaccine Group is leading another a study aimed at an older age group, investigating whether giving a MenB vaccine to teenagers reduces carriage of this bacteria, potentially providing protection to all ages from this dangerous infection.

If you would like to take part in the Be on the TEAM (TEenagers Against Meningitis) study, please take a look at the project website.


Similar stories

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.